Related references
Note: Only part of the references are listed.A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability
Carolin Temps et al.
CANCER RESEARCH (2021)
Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors
Katharina Rothe et al.
CELL STEM CELL (2020)
Src Family Kinases as Therapeutic Targets in Advanced Solid Tumors: What We Have Learned So Far
Stefano Martellucci et al.
CANCERS (2020)
The focal adhesion protein Integrin-Linked Kinase (ILK) as an important player in breast cancer pathogenesis
Katerina Tsirtsaki et al.
CELL ADHESION & MIGRATION (2020)
Identifying chemogenetic interactions from CRISPR screens with drugZ
Medina Colic et al.
GENOME MEDICINE (2019)
A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells
Henry Beetham et al.
SCIENTIFIC REPORTS (2019)
The Small Molecule Inhibitor QLT-0267 Decreases the Production of Fibrin-Induced Inflammatory Cytokines and Prevents Post-Surgical Peritoneal Adhesions
Cheng-Chung Fang et al.
SCIENTIFIC REPORTS (2018)
Dasatinib sensitises triple negative breast cancer cells to chemotherapy by targeting breast cancer stem cells
Jun Tian et al.
BRITISH JOURNAL OF CANCER (2018)
Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities
Kendall R. Sanson et al.
NATURE COMMUNICATIONS (2018)
The target landscape of clinical kinase drugs
Susan Klaeger et al.
SCIENCE (2017)
Evaluation and Design of Genome-Wide CRISPR/SpCas9 Knockout Screens
Traver Hart et al.
G3-GENES GENOMES GENETICS (2017)
Optimised metrics for CRISPR-KO screens with second-generation gRNA libraries
Swee Hoe Ong et al.
SCIENTIFIC REPORTS (2017)
Rationally engineered Cas9 nucleases with improved specificity
Ian M. Slaymaker et al.
SCIENCE (2016)
Modulation of FAK and Src adhesion signaling occurs independently of adhesion complex composition
Edward R. Horton et al.
JOURNAL OF CELL BIOLOGY (2016)
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase
Craig Fraser et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
John G. Doench et al.
NATURE BIOTECHNOLOGY (2016)
The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
Bernard Pereira et al.
NATURE COMMUNICATIONS (2016)
Chelidonine suppresses migration and invasion of MDA-MB-231 cells by inhibiting formation of the integrin-linked kinase/PINCH/α-parvin complex
Okhwa Kim et al.
MOLECULAR MEDICINE REPORTS (2015)
Definition of a consensus integrin adhesome and its dynamics during adhesion complex assembly and disassembly
Edward R. Horton et al.
NATURE CELL BIOLOGY (2015)
A Comparison of Real-Time and Endpoint Cell Viability Assays for Improved Synthetic Lethal Drug Validation
Andrew Single et al.
JOURNAL OF BIOMOLECULAR SCREENING (2015)
Gene Signature-Guided Dasatinib Therapy in Metastatic Breast Cancer
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Genome engineering using the CRISPR-Cas9 system
F. Ann Ran et al.
NATURE PROTOCOLS (2013)
KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals
S. Moleirinho et al.
ONCOGENE (2013)
Overexpression of ILK1 in breast cancer associates with poor prognosis
Hong-Jian Yang et al.
TUMOR BIOLOGY (2013)
Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy
M. Campone et al.
ANNALS OF ONCOLOGY (2012)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Integrin-linked kinase at a glance
Moritz Widmaier et al.
JOURNAL OF CELL SCIENCE (2012)
Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study
Richard S. Finn et al.
CLINICAL CANCER RESEARCH (2011)
Identification and Characterization of a Novel Integrin-Linked Kinase Inhibitor
Su-Lin Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A public genome-scale lentiviral expression library of human ORFs
Xiaoping Yang et al.
NATURE METHODS (2011)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
John Colicelli
SCIENCE SIGNALING (2010)
Molecular dissection of the ILK-PINCH-parvin triad reveals a fundamental role for the ILK kinase domain in the late stages of focal-adhesion maturation
Fabio Stanchi et al.
JOURNAL OF CELL SCIENCE (2009)
The Pseudoactive Site of ILK Is Essential for Its Binding to α-Parvin and Localization to Focal Adhesions
Koichi Fukuda et al.
MOLECULAR CELL (2009)
Cell adhesion-dependent cofilin serine 3 phosphorylation by the integrin-linked kinase•c-Src complex
Yong-Bae Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells
Adina Vultur et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: Rationale for patient selection
Fei Huang et al.
CANCER RESEARCH (2007)
A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo
Houda Jallal et al.
CANCER RESEARCH (2007)
CellProfiler: image analysis software for identifying and quantifying cell phenotypes
Anne E. Carpenter et al.
GENOME BIOLOGY (2006)
Inhibition of integrin-linked kinase by QLT0254 inhibits Akt-dependent pathways and is growth inhibitory in orthotopic primary pancreatic cancer xenografts
CYF Yau et al.
CANCER RESEARCH (2005)
Share Paper
